Nathalie Mielcarek, Ph.D.

Nathalie Mielcarek, Ph.D. , serves as a member of ILiAD’s Scientific Advisory Board. Dr. Mielcarek is a research director at the French National Institute of Health and Medical Research (Inserm). She is based at the Institut Pasteur de Lille, France. Dr. Mielcarek has a long-standing interest and experience in infectious diseases and vaccine development. She obtained her PhD from the University of Lille, France in 1996 for her work on vaccine development against schistosomiasis at the Institut Pasteur de Lille (IPL). She then received a Marie Curie fellowship to support her postdoctoral research on mucosal vaccination at the University of Göteborg, Sweden. In 2000, she returned to IPL to develop a novel nasal live attenuated vaccine against pertussis (BPZE1) which is currently under clinical development. From 2006 to 2009, she joined the International Vaccine Institute, in Seoul, South Korea where she initiated a research program on sublingual immunization against tuberculosis. Since her return to France, she coordinates international programs dedicated to preclinical and clinical developments of vaccines against whooping-cough and against tuberculosis. Nathalie Mielcarek is also the head of International Relations of the Institut Pasteur de Lille, hosting 32 research teams dedicated to infectious diseases, cancer, diabetes, cardiovascular and neurodegenerative diseases.

Copyright 2013-2017 ILiAD Biotechnologies